JAMA Oncol: Triple negative breast cancer treatment added "platinum program", five-year disease-free survival rate of 86.5%

Recently, a study published by Professor Zhai Zhimin of Breast Surgery and Professor Yu Koda of Fudan University's Affiliated Oncology Hospital confirmed that the "platinum solution" for three-negative breast cancer treatment - the week-long intensive application of the chemotherapy drug yew alcohol combination carpentin ("platinum" commonly known as "platinum", "carpentry" is platinum-containing chemotherapy drugs), can improve the five-year survival rate of such patients to 86.5 percent, far higher than the standard complementary chemotherapy program.
is also the first clinical study in the world to successfully confirm the benefits of platinum-containing programmes in postoperative complementary treatment for triple-negative breast cancer.
13, the results were published online in JAMA, the top international journal.
Efficacy "bottleneck": "three Yin" characteristics lead to the precise program lack of breast cancer is the highest incidence of malignant tumors in women, of which three negative breast cancer is the most malignant subtype of all breast cancer, accounting for about 15-20% of all breast cancer.
because of its high risk of recurrence metastasis, treatment effect is poor, and let many breast cancer patients smell color change.
Three negative breast cancer is called "three yin", precisely because of its three important molecules: estrogen-like, progesterone-like, HER2 are expressed as negative - and these three molecules are precisely the current breast cancer endocrine therapy and anti-HER2 targeted treatment of an important basis, so "three yin" has also become the poor efficacy of this type of breast cancer "the culprit."
" current early breast cancer through standardized comprehensive treatment, the overall five-year disease-free survival rate can be close to 90%.
However, due to the characteristics of tri-negative breast cancer, the efficacy of this type of breast cancer is significantly lower than that of other types of breast cancer," said Professor Zhai Zhimin, Director of Breast Cancer Surgery at Cancer Hospital. Auxiliary program, but the five-year disease-free survival rate under this program has been hovering around 80%, in recent years, although some studies have shown that new platinum-containing auxiliary program or rescue program can be applied to triple-negative breast cancer, but whether it can be applied to postoperative auxiliary treatment of patients, still need to be further confirmed by clinical practice.
": The world's first confirmed effect of the platinum-type three-negative breast cancer program as early as 10 years ago, Professor Zhai Zhimin's team began to work on the three-negative breast cancer series of research.
the dilemma of whether we can improve the efficacy of three-negative breast cancer by optimizing the drug and improving the program has become one of the key "attack" directions of Professor Zhai Zhimin's team.
Previous basic studies have confirmed that about 10% of patients with triple-negative breast cancer have mutations in the anti-cancer gene BRCA1/2, leading to cellular gene instability, while other non-BRCA1/2 mutations caused by genomic instability, is also very common in triple-negative breast cancer.
main mechanism of action of platinum chemotherapy drugs is to destroy the genes of cells, and thus kill tumors, which may have good effect on breast cancer patients with embryo BRCA1/2 gene mutations and ogenetic recombination repair defects.
, can platinum-containing chemotherapy be the optimal choice for triple-negative breast cancer? To this end, with the support of Shanghai Shenkang Emerging Technology Project, Professor Zhai Zhimin and Professor Yu Koda's team have conducted a multi-center randomized controlled phase III clinical study in nine hospitals within the United Nations since 2011.
study included 647 women with triple-negative breast cancer, spanned from July 2011 to April 2016.
patients in the
group were randomly divided into two groups, of which 325 patients in the trial group were treated with a single-week intensive use of the yew alcohol combined carbapa platinum programme for a total of 6 cycles, and 322 control group patients were treated with a combined programme of cyclophosphamide/table-soft star/fluorouracil sequence through dositamine recommended by the guidelines at the time.
after more than 5 years of follow-up statistics, the five-year disease-free survival rate of patients with triple-negative breast cancer who received the carpentre platinum scheme (PCb scheme) reached 86.5%, higher than the 80.3% of the CF-T scheme recommended by the guidelines. P s 0.03). The five-year no-distance transfer rate reached 92.6%, which was also significantly higher than the control group's 87.9%.
, the risk of recurrence metastasis was 61% lower in patients with BRCA1/2 equivalent recombinant repair gene mutations than in standard scenarios.
Figure 2. Professor Yu Koda, deputy director of breast surgery at Disease-Free Survival and Overall Survival Cancer Hospital, said the large-scale clinical study, initiated by the Chinese people, was the first in the world to confirm that the efficacy of the postoperative chemotherapy drug yew alcohol combined with carptonine for triple-negative breast cancer was significantly better than that of traditional standard chemotherapy programmes.
especially for patients with triple-negative breast cancer who have poor heart conditions and are not resistant to cycloplasmotic chemotherapy drugs, platinum-containing options are preferred.
Symbody Fist": Three-negative breast cancer is expected to achieve precision treatment" as Fudan University Affiliated Cancer Hospital for three-negative breast cancer series of research, this method by optimizing different combinations of chemotherapy drugs to obtain a five-year disease-free survival of 6.2% of the welcome breakthrough, in order to crack the three-yin "The research team will continue to explore specific targets and markers of triple negative breast cancer to guide future targeted treatment, combined with the results of this series of studies, will lay a more solid foundation for the precise treatment of triple negative breast cancer," said Professor Zhai Zhimin.
" In recent years, Professor Zhai Zhimin's team has launched a series of "combination punches" for three-negative breast cancer: the team led a number of multi-center three-negative breast cancer research results published in international authoritative journals, and included in the international treatment guidelines.
e.g., to map the world's largest three-negative breast cancer cohort multi-group, breaking through past understanding, confirming that triple-negative breast cancer is not a single type, while further dividing the subtypes of triple-negative breast cancer according to different genetic characteristics, and exploring the mechanism of key driving genes (the results are published in Cansr Cell, Mol, Cancer) Sci Adv et al.) Based on basic research, the team has also conducted a series of studies such as "Future Study" (published in Cell Res), "CBCSG-010 Study" (Results published in J Clin Oncol), etc., and proposed a joint Capabin chemotherapy enhancement program to significantly improve the efficacy of triple negative breast cancer... Highlights of the "Fudan program" for the three-negative breast cancer precision program development has brought more hope.
.